Previous studies have shown that IRF5 mediates joint inflammation by integrating Toll-like receptor signals and regulating proinflammatory cytokine and chemokine production in a mouse model [51, 52], and its inhibition suppresses SLE onset and progression in mice [53, 54]. Here, IRF5 is linked to systemic lupus erythematosus.